(Q28165707)

Cardiology and cardiovascular medicine

title

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program (English)

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0002-8703(03)00398-3

22 March 2024

author name string

Alise Reicin

3

0 references

Matthew R. Weir

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14564311

22 March 2024

Rhoda S. Sperling

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14564311

22 March 2024

Barry J. Gertz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14564311

full work available at URL

22 March 2024

language of work or name

English

0 references

publication date

October 2003

0 references

https://api.elsevier.com/content/article/PII:S0002870303003983?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0002-8703(03)00398-3

https://api.elsevier.com/content/article/PII:S0002870303003983?httpAccept=text/plain

22 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0002-8703(03)00398-3

The coxibs, selective inhibitors of cyclooxygenase-2.

22 March 2024

published in

American Heart Journal

0 references

volume

146

0 references

issue

4

0 references

page(s)

591-604

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Clinical pharmacology of platelet cyclooxygenase inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Platelet-active drugs: the relationships among dose, effectiveness, and side effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Cyclooxygenase-2 and atherosclerosis: friend or foe?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Atherosclerosis — An Inflammatory Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Risk of cardiovascular events associated with selective COX-2 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Recovery of Endothelial Cell Prostacyclin Production after Inhibition by Low Doses of Aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Altered pain perception and inflammatory response in mice lacking prostacyclin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Role of prostacyclin in the cardiovascular response to thromboxane A2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Pharmacological modulation, preclinical studies, and new clinical features of myocardial ischemic preconditioning.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Aspirin, but not the more selective cyclooxygenase (COX)-2 inhibitors meloxicam and SC 58125, aggravates postischaemic cardiac dysfunction, independent of COX function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Relative risk of cardiovascular events in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

The mortality of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Mortality in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Blood pressure, stroke, and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Renal effects of COX-2-selective inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

An updated coronary risk profile. A statement for health professionals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Indobufen: an updated review of its use in the management of atherothrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Antithrombotic therapy in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Nonsteroidal anti-inflammatory drugs after acute myocardial infarction. DAVIT Study Group. Danish Verapamil Infarction Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Association between naproxen use and protection against acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Nonsteroidal antiinflammatory drugs after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Rational use of analgesic and antiinflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

Cyclooxygenase inhibition and thrombogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900398-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Cyclo-oxygenase products and atherothrombosis

35

1 reference

https://api.crossref.org/works/10.1016/S0002-8703(03)00398-3

22 March 2024

Identifiers

0 references